← Back to Search

Antiparasitic

intranasal Ivermectin group for Loss of Smell

Phase 2 & 3
Waitlist Available
Research Sponsored by South Valley University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 14 days after enrollemen ]
Awards & highlights
All Individual Drugs Already Approved

Summary

ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 14 days after enrollemen ]
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 14 days after enrollemen ] for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
regaining of smell

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: intranasal Ivermectin groupActive Control1 Intervention
49 pateints with anosmia received ivermectin nanosuspension nasal spray
Group II: saline nasal sprayPlacebo Group1 Intervention
47 pateints with anosmia received saline nasal spray

Find a Location

Who is running the clinical trial?

South Valley UniversityLead Sponsor
112 Previous Clinical Trials
13,932 Total Patients Enrolled
~26 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top